The Next Generation
Biology has moved from a descriptive science to one that allows scientists to engineer potential new types of therapeutic antibodies. What's next?
RT @krystadawn: Lots of important topics at #ASCO13:QoL, combos,immunotherapies,nextgen antibodies...visit gene.com/asco for...
#ASCO13 MT @centenaryinst: Lovely animation communicating cancer research. RT @genentech: 2 scientists solve myste... ow.ly/lDpe6
MT @lungproject: #Healthcare professionals aren't immune to #lungcancer bias. See how you compare: bit.ly/R8VhJM #ASCO13
What one of our #Genentech scientists dreamt about before #ASCO13. Read on: bit.ly/10JmlU8 ow.ly/i/2gaUh
RT @genentech: #ASCOIQ: Proof of concept for anti-VEGF came from #Genentech data 10 yrs before #ASCO13 bit.ly/143Nf91 twitter.com/rx…
MT @gene_antibody: humor - What d'u get when u combine an ADC & another therapeutic antibody? A smart combo! #ASCO13 bit.ly/12nF1fe
Case of the Wild Kinase: How 2 scientists exposed a paradox that made them rethink how they research #ASCO13 Watch: bit.ly/10JY8gg
#DidYouKnow? A NCI-sponsored trial of a #Genentech medicine was in the #ASCO13 plenary this afternoon ow.ly/i/2eCQZ
20 meds now have breakthrough designation. Unclear on what it means and why it’s important? Read: bit.ly/16zBnAh #ASCO13
& get a cookie! RT @gene_antibody: So cool to see how #Genentech builds its #ASCO13 booth. Meet me there! bit.ly/11x2oLN

Biology has moved from a descriptive science to one that allows scientists to engineer potential new types of therapeutic antibodies. What's next?

Everyone is talking about the medical implications of big data. Read 5 things big data can and can't do in cancer research.
Read our press releases, explore our data, and learn about what we're presenting at the 49th meeting of the American Society of Clinical Oncology.

Genentech scientists came across a boggling observation. Take a look at a discovery that may have important implications for personalized medicine.

This year at ASCO, we’ll see data from clinical trials on the most cutting-edge approaches to cancer treatment. Beyond the numbers, how are patients actually feeling?

There is tremendous hope to transform cancer into a manageable disease with combinations of targeted medicines.

The relationship between companies and researchers is critical as both play an important role in bringing new medicines to people with cancer.

Conscious and subconscious perceptions influence the way we view race, wealth and gender. But what about cancer?

The science behind our medicines is complex. We've brought along some friends to help us explain it.

Dr. Hal Barron, talks about Expanded Access Programs (EAP), compassionate use, and how we address access to unapproved medicines.

Scientists first considered the prospect of harnessing the body's own immune system to fight cancer more than 100 years ago.

Stay sharp during downtime at ASCO 2013. Download our iPad app that integrates science and technology into a fun and smart game.

Test your knowledge of conference jargon and oncology terminology with our flashcards.

Sandra Horning, Global Head of Oncology, shares her experiences attending ASCO over the last 34 years, and fighting cancer in multiple ways.